These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 28343336)

  • 1. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
    Buda-Nowak A; Kucharz J; Dumnicka P; Kuzniewski M; Herman RM; Zygulska AL; Kusnierz-Cabala B
    Med Oncol; 2017 Apr; 34(4):68. PubMed ID: 28343336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
    Sella A; Hercbergs AH; Hanovich E; Kovel S
    Chemotherapy; 2012; 58(3):200-5. PubMed ID: 22759787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
    Bozkurt O; Karaca H; Hacıbekiroglu I; Kaplan MA; Duzkopru Y; Uysal M; Berk V; Inanc M; Duran AO; Ozaslan E; Ucar M; Ozkan M
    J Chemother; 2016 Jun; 28(3):230-4. PubMed ID: 25948423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
    Baldazzi V; Tassi R; Lapini A; Santomaggio C; Carini M; Mazzanti R
    Urol Oncol; 2012 Sep; 30(5):704-10. PubMed ID: 20884255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
    Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.
    Kucharz J; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Herman RM; Krzemieniecki K
    Tumori; 2015; 101(5):555-9. PubMed ID: 26045121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
    Sabatier R; Eymard JC; Walz J; Deville JL; Narbonne H; Boher JM; Salem N; Marcy M; Brunelle S; Viens P; Bladou F; Gravis G
    Ann Oncol; 2012 Mar; 23(3):714-721. PubMed ID: 21653681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
    Bourlon MT; Gao D; Trigero S; Clemons JE; Breaker K; Lam ET; Flaig TW
    Cancer Med; 2016 Dec; 5(12):3386-3393. PubMed ID: 27758076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma.
    Kucharz J; Giza A; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Bryniarski P; Herman R; Zygulska AL; Krzemieniecki K
    Med Oncol; 2016 Oct; 33(10):109. PubMed ID: 27573381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer.
    Vasileiadis T; Chrisofos M; Safioleas M; Kontzoglou K; Papazisis K; Sdrolia A
    BMC Cancer; 2019 Apr; 19(1):407. PubMed ID: 31039771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
    Riesenbeck LM; Bierer S; Hoffmeister I; Köpke T; Papavassilis P; Hertle L; Thielen B; Herrmann E
    World J Urol; 2011 Dec; 29(6):807-13. PubMed ID: 21153827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
    Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; de Cobelli O; Nolè F
    Anticancer Drugs; 2017 Feb; 28(2):206-212. PubMed ID: 27754995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
    Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R
    Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
    Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
    Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
    Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
    Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.